Real world comparison of major bleeding risk among non-valvular atrial fibrillation patients newly initiated on apixaban, dabigatran, rivaroxaban or warfarin

被引：0
|
作者：
Lip, G. Y. H. [1 ]
Pan, X. [2 ]
Kamble, S. [2 ]
Kawabata, H. [2 ]
Mardekian, J. [3 ]
Masseria, C. [3 ]
Bruno, A. [2 ]
Phatak, H. [2 ]
机构：
[1] Univ Birmingham, Birmingham, W Midlands, England
[2] Bristol Myers Squibb Co, Princeton, NJ USA
[3] Pfizer Inc, New York, NY USA
来源：
EUROPEAN HEART JOURNAL | 2015年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P6217
引用
收藏
页码：1085 / 1085
页数：1
相关论文
共 50 条
  • [21] Direct comparison of dabigatran, apixaban, rivaroxaban and edoxaban for effectiveness and safety among patients with non-valvular atrial fibrillation
    Choi, E. -K.
    Lee, S. R.
    Kwon, S.
    Han, K. D.
    Jung, J. H.
    Oh, S.
    Lip, G. Y. H.
    EUROPEAN HEART JOURNAL, 2019, 40 : 2986 - 2986
  • [22] Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population
    Amin, Alpesh
    Keshishian, Allison
    Trocio, Jeffrey
    Dina, Oluwaseyi
    Le, Hannah
    Rosenblatt, Lisa
    Liu, Xianchen
    Mardekian, Jack
    Zhang, Qisu
    Baser, Onur
    Lien Vo
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (09) : 1595 - 1604
  • [23] EFFECTIVENESS AND SAFETY OF APIXABAN, DABIGATRAN, AND RIVAROXABAN COMPARED TO WARFARIN AMONG NON-VALVULAR ATRIAL FIBRILLATION PATIENTS IN THE US MEDICARE POPULATION
    Amin, Alpesh
    Keshishian, Allison
    Trocio, Jeffrey
    Le, Hannah
    Dina, Oluwaseyi
    Zhang, Qisu
    Baser, Onur
    Vo, Lien
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 316 - 316
  • [24] Real-world comparison of major bleeding and associated costs among treatment-naive non-valvular atrial fibrillation patients initiating apixaban or warfarin
    Amin, A.
    Keshishian, A. V.
    Xie, L.
    Baser, O.
    Price, K.
    Vo, L.
    Mardekian, J.
    Mendoza, M.
    Singhal, S.
    Patel, C.
    Odell, K.
    Trocio, J.
    EUROPEAN HEART JOURNAL, 2016, 37 : 506 - 506
  • [25] Real-world comparison of major bleeding and associated costs among treatment-naive non-valvular atrial fibrillation patients initiating apixaban or warfarin
    Amin, Alpesh
    Keshishian, Allison
    Xie, Lin
    Baser, Onur
    Price, Kwanza
    Vo, Lien
    Mardekian, Jack
    Mendoza, Mario
    Singhal, Shalabh
    Patel, Chad
    Odell, Kevin
    Trocio, Jeffrey
    PHARMACOTHERAPY, 2016, 36 (12): : E214 - E214
  • [26] Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation
    Adeboyeje, Gboyega
    Sylwestrzak, Gosia
    Barron, John J.
    White, Jeff
    Rosenberg, Alan
    Abarca, Jacob
    Crawford, Geoffrey
    Redberg, Rita
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (09): : 968 - 978
  • [27] Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
    Andersson, Niklas W.
    Svanstrom, Henrik
    Lund, Marie
    Pasternak, Bjorn
    Melbye, Mads
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 268 : 113 - 119
  • [28] REAL-WORLD COMPARISON OF INPATIENT BLEEDING RISK, BLEEDING-RELATED HOSPITALIZATION RATES AND COSTS AMONG NON-VALVULAR ATRIAL FIBRILLATION PATIENTS ON APIXABAN, DABIGATRAN, RIVAROXABAN: COHORTS COMPRISING NEW INITIATORS AND/OR SWITCHERS FROM WARFARIN
    Tepper, Ping
    Mardekian, Jack
    Masseria, Cristina
    Horblyuk, Ruslan
    Kamble, Shital
    Hamilton, Melissa
    Abdulsattar, Younos
    Petkun, William
    Lip, Gregory Y. H.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 662 - 662
  • [29] Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
    Kjerpeseth, Lars J.
    Selmer, Randi
    Ariansen, Inger
    Karlstad, Oystein
    Ellekjaer, Hanne
    Skovlund, Eva
    PLOS ONE, 2019, 14 (08):
  • [30] REAL WORLD DISCONTINUATION RATES WITH APIXABAN VERSUS WARFARIN, DABIGATRAN, OR RIVAROXABAN AMONG ATRIAL FIBRILLATION PATIENTS NEWLY INITIATED ON ANTICOAGULATION THERAPY: EARLY FINDINGS
    Pan, Xianying
    Kachroo, Sumesh
    Liu, Xianchen
    Kawabata, Hugh
    Phatak, Hemant
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (12) : A415 - A415
12345